Prelude Therapeutics Inc.

PRLD

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001678660

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $141.3M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 10, 2026 245 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$3.76 2026-11-09; market equity $300.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 10, 2026

Prelude Therapeutics Incorporated ("Prelude" or the "Company") is a precision oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. By leveraging our core competencies in cancer biology and medicinal chemistry, combined with our clinical development capabilities, we have built an efficient, drug discovery engine and the development expertise necessary to identify compelling biological targets and create new chemical entities, or NCEs, that we advance into clinical trials. We believe our approach could result in better targeted cancer therapies.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 15.5						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(27.3%)	(6.6%)	15.5	800	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 71.9						
Twelve-month failure probability	not computable	0.08%				
liabilities and a nearby cover-page share count are required at 2025-12-31						
Altman Z double-prime	(17.29)	(0.35)	71.9	745	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	1.99x	2.95x	71.9	826	2025-12-31	
Growth and financing, sleeve percentile 65.2						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 2						
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(13.8%)	2.2%	74.7	694	2025-12-31	
Net share issuance, one year	14.2%	2.5%	55.7	629	2026-03-06	

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	145.9%	(1.9%)	94
Distance from 52-week high	(43.3%)	(27.5%)	34
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(18.8%)	(1.0%)	24
Book value to price	0.45	0.27	65
Sales to price	0.04	0.29	15
Composite equity issuance, five years	53.8%	20.8%	66
Relative strength against the sector, log excess return	0.73	(0.19)	94

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	pass

Cash, filings, liquidity

Cash and equivalents	$26.3M
Operating cash flow, four quarters	-$33.3M
Months of runway	9.5
Days since last periodic filing	91 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$1.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$99.5M	2025-12-31	2026-03-10	10-K	26-099428
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$56.3M	2025-12-31	2026-03-10	10-K	26-099428
3	assets	us-gaap:Assets	$141.3M	2025-12-31	2026-03-10	10-K	26-099428
4	assets	us-gaap:Assets	$175.5M	2024-12-31	2026-03-10	10-K	26-099428
5	current assets	us-gaap:AssetsCurrent	$105.7M	2025-12-31	2026-03-10	10-K	26-099428
6	current liabilities	us-gaap:LiabilitiesCurrent	$53.0M	2025-12-31	2026-03-10	10-K	26-099428
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$683.1M	2025-12-31	2026-03-10	10-K	26-099428
8	operating income	us-gaap:OperatingIncomeLoss	-$104.6M	2025-12-31	2026-03-10	10-K	26-099428
9	book equity	us-gaap:StockholdersEquity	$68.6M	2025-12-31	2026-03-10	10-K	26-099428
10	liabilities	us-gaap:Liabilities	$72.7M	2025-12-31	2026-03-10	10-K	26-099428
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$12.1M	2025-12-31	2026-03-10	10-K	26-099428
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$7.0M	2024-12-31	2026-03-10	10-K	26-099428
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$67,000	2025-12-31	2026-03-10	10-K	26-099428
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$102.9M	2024-12-31	2026-03-10	10-K	26-099428
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$764,000	2024-12-31	2026-03-10	10-K	26-099428
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$107.1M	2023-12-31	2025-03-10	10-K	25-035921
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.5M	2023-12-31	2025-03-10	10-K	25-035921
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$83.7M	2022-12-31	2024-02-15	10-K	24-016016
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.0M	2022-12-31	2024-02-15	10-K	24-016016
20	assets	us-gaap:Assets	$277.7M	2023-12-31	2025-03-10	10-K	25-035921
21	assets	us-gaap:Assets	$220.5M	2022-12-31	2024-02-15	10-K	24-016016
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,002,248	2026-03-06	2026-03-10	10-K	26-099428
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	55,154,634	2025-03-06	2025-03-10	10-K	25-035921

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.